Adial Pharmaceuticals, Inc. (NASDAQ:ADIL;ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, reports that its lead drug candidate, AD04, a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes, has been featured on local TV
December 4, 2020
· 3 min read